Episode 71: Covid-19 pandemic trajectory - What you need to know
Episode 71: Covid-19 pandemic trajectory - What you need to know 19 January 2021 10:57 Gustav Ando We have entered 2021 with the pandemic still...
Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Customer LoginsMr. Ando oversees the development of IHS Markit's global healthcare outlook analysis that focuses on market access, cost of healthcare and new treatment advances as well as coordinating its ongoing thinking on COVID-19. He heads the research and data teams that produce daily analysis, risk assessment and critical data for the pharmaceutical industry, as well as the consulting team that focuses on disease prevention, workforce and demand healthcare microsimulation models. With more than 15 years of experience in the industry, he is a regular speaker at conferences and is frequently cited by major media publications and national radio and television programs. He is the author and podium presenter of research at numerous academic conferences such as ISPOR. Mr Ando also oversees our global comparative industry group which provide critical long-term forecast perspectives across all industries around the world, as well as our specialised global constructrion group. Mr. Ando holds a postgraduate degree from the University of Uppsala, Sweden, and an undergraduate degree from the University of Durham in the United Kingdom.
While the COVID-19 virus will be with us throughout 2021, the rapid development and deployment of vaccines will enable a transition to a new post-pandemic economy. The global economy will enter 2021 at a subdued growth pace and gain momentum as the year progresses.
Kari Jones, Ph.D.
Consulting Associate Director, Life Sciences
Janet Beal
Senior Research Analyst, Life Sciences, IHS Markit
Dr. Mark Morgan, Ph.D.
Vice President, Chemicals Consulting